In 2025 the Measles outbreak in the U.S. reached record highs: at least 1,288 confirmed cases across 39 states, surpassing the last peak in 2019 and far exceeding 285 cases in 2024.[iii] Meanwhile, the global Mpox epidemic (Jan 2022–Nov 2024) has seen more than 118,000 confirmed cases across over 120 countries. Against this backdrop of spiraling outbreaks and limited therapeutic options, the broad-spectrum drug candidate NV 387 (by NanoViricides, Inc./NNVC) — currently in development for RSV, Influenza/Bird flu, COVID/long COVID, Measles, Mpox/smallpox and more — presents a timely opportunity to invest in the development of a revolutionary “first visit” anti-viral treatment that is safe, nontoxic and works even as variants emerge..
|
NanoViricides
March 11, 2026 • 3 min read |
|
|
NanoViricides
February 12, 2026 • 10 min read |
|
|
NanoViricides
February 2, 2026 • 9 min read |
While bacterial infections are treated on “first visit” with broad spectrum antibiotics, the world still lacks effective, broad-spectrum therapies that can treat viral infections immediately after symptoms appear, without waiting for tests to determine which virus. That is why outbreaks of Mpox, RSV, Influenza, COVID-19, and Measles continue to surge, despite rapid advances in vaccines, with millions affected globally each year.
Existing treatments are virus-specific and quickly lose effectiveness as viruses mutate into variants. In many viral infections, especially emerging and re-emerging diseases, no direct therapeutic treatment drugs exist.
The growing frequency of pandemics and falling vaccination rates highlight a major unmet medical need: a safe, nontoxic broad-spectrum antiviral therapy capable of addressing multiple viral threats simultaneously. NanoViricides’ NV-387 directly targets this global gap with its innovative Bind–Engulf–Destroy mechanism.
NNVC is now pursuing a dual track strategy for clinical development. The first trial will be against MPox virus, a relative of smallpox. The second is in respiratory viral diseases. NV's lead molecule NV-387 has already completed a Phase 1 study in 2023 showing safety and tolerability.
The global rise of viral diseases — from COVID-19 and RSV to Mpox and Measles — continues to highlight a critical gap in modern healthcare: the lack of a single, broad-spectrum antiviral that can address multiple infections effectively. Traditional vaccines and virus-specific drugs remain limited in speed, scope, and adaptability.
NanoViricides, Inc. (NYSE American: NNVC) has developed a breakthrough solution with its lead candidate NV-387, a first-of-its-kind antiviral designed to bind, engulf, and destroy virus particles before they infect cells. NV-387 has completed Phase I trials showing excellent safety and is advancing into Phase II for Mpox and respiratory viral infections.
With a potential market exceeding $11 Billion in 2025 across major viral indications, NanoViricides is positioned at the intersection of medical innovation and global preparedness. Its technology platform is built for versatility — capable of addressing emerging and even unknown viral threats without the delays of conventional drug development.
Investors* and analysts keeping a close watch on the antiviral sector should keep NanoViricides on their radar — a company with the science, data, and timing to potentially redefine the global antiviral therapeutics market.
NanoViricides, Inc. (NYSE American: NNVC) is a clinical-stage biopharmaceutical company leading a breakthrough revolution in antiviral drug development through its proprietary nanoviricide® nanomedicine platform xvi. This platform is designed to create virus-targeted nanomachines that bind to, encapsulate, and destroy viruses — a novel “Bind–Encapsulate–Destroy” mechanism that goes beyond the capabilities of antibodies or vaccines.
The company’s lead candidate, NV-387, is a broad-spectrum antiviral currently advancing toward Phase II clinical trials, targeting major global threats such as COVID/long COVID, Influenza/Bird Flu, RSV, MPox/Smallpox, and Measles. Alongside, NanoViricides has developed NV-HHV-1, a topical antiviral for Shingles, Cold Sores, and Genital Ulcers, forming part of its HerpeCide™ program.
NanoViricides stands apart as one of the few biotechnology companies with its own cGMP-compliant, multi-product manufacturing facility in Shelton, CT — capable of producing both drug substances and final drug products for clinical trials. This advanced facility enables rapid clinical-scale production and significantly reduces dependency on third-party manufacturers (better quality control, lower IP risk, lower cost). Further, it is capable of initial market-scale production, enabling early revenues of approximately $100 million to $500 million per year upon drug approval.
With a strong intellectual property foundation, innovative technology, and expanding clinical pipeline, NanoViricides is positioned to redefine antiviral therapy and preparedness against future viral pandemics.
NanoViricides has developed nanoviricides® capable of binding up to 90–95% of known viruses since all of them are based on Heparin Sulfate, targeting shared viral mechanisms. Lead candidate NV-387 fights RSV, COVID-19, Influenza, and Smallpox/MPox, while NV-HHV-1 targets Shingles and other Herpes viruses. Additional nanoviricides are in development against Dengue, Rabies, and Ebola/Marburg, showcasing the platform’s unmatched versatility.
Dr. Diwan has been President and Chairman of the Board of the Company since its founding in 2005 Dr. Diwan spearheaded the efforts for the Company's 2013 uplisting from the OTC Markets to NYSE-American. Dr. Diwan has led several of the Company's financing efforts since 2010.
Dr. Diwan invented novel polymeric micelle-based nanomedicine technologies as early as 1991. Dr. Diwan is a prolific inventor and a serial entrepreneur. Prior to co-founding NanoViricides, Inc., he has founded TheraCour Pharma, Inc., a privately held company focused in nanomedicines and cell-targeted drug delivery, and AllExcel, Inc., a company with diverse portfolios including nanomedicines, small chemicals, device technologies, as well as informatics. He has won several NIH SBIR (small business innovation research) grant awards. Anil holds a Ph.D. from Rice University, TX, a B.Tech. from Indian Institute of Technology, Mumbai (IIT-B), India, and has consistently held high scholastic ranks and honors. Dr. Diwan has over 25 years of Bio-Pharmaceutical R&D experience with over 20 years as an entrepreneur.
He has several patents issued internationally resulting from three fundamental international patent applications. Under Dr. Diwan's leadership, NanoViricides, Inc. has been able to keep both administrative and R&D costs at extremely low levels while robustly expanding the drug pipeline every year. Dr. Anil R. Diwan was recognized as "Researcher of the Year" by BusinessNewHaven, a Connecticut Area Business Journal, in 2014.
Ms. Vyas is known as a strong leader with board level experience and successful achievements as a Senior Executive in a broad range of entities including publicly listed corporations, non-revenue generating entities, and medium to large size companies. Meeta has over twenty-five years of experience in performance and process improvement of both publicly listed companies and non-revenue producing entities, in areas ranging from Finance and Operations to Strategy and Management. Meeta holds the distinction of being the first Indian woman to be named CEO of a publicly listed US corporation, Signature Brands, Inc., best known for "Mr. Coffee" and "Health-O-Meter" brand products. As CEO, acting COO and Vice Chairman of the Board of Signature Brands, Inc., she was responsible for the development and implementation of a turnaround plan, resulting in a return to profitability and growth within a short period of time. Later, as the CEO of the World-Wide Fund for Nature - India (WWF-India) and then as a Vice President of the National Audubon Society (USA), both non-revenue generating entities, Meeta successfully raised unrestricted funding that significantly exceeded annual requirements and also instituted financial processes to measure a variety of performance metrics. Earlier in her career, she was responsible for designing the strategy and initiating the implementation plan for the highly successful information technology outsourcing program at General Electric (GE). Also at GE, Ms. Vyas ran GE Appliances' Range Products business unit having revenues exceeding $1 Billion where her team doubled operating income in less than two years. Prior to that, as a management consultant with McKinsey and Company, she served publicly listed companies in chemicals, industrial, and technology markets, primarily focusing on growth strategies, valuations, post-merger integrations, and logistics operations. Meeta is married to NanoViricides, Inc. President and Chairman Anil R. Diwan.
Ms. Vyas holds a MBA in Finance from Columbia University's Graduate School of Business, and a BS in Chemical Engineering from the Massachusetts Institute of Technology. NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector.
Jay Tatake is an organic chemist with over 25 years of experience in Research and Process Development of fine chemicals. His experience encompasses production scale-up, and large scale manufacture of raw materials for pharmaceuticals. Before joining NanoViricides, Inc., he was Assistant Director of Analytical R&D at Interpharm, Inc. Prior to that, he was Director of Analytical Services at Pharmax Group, Inc. Dr. Tatake has several years experience in Analytical methods development and Quality Control in cGMP environment. His experience includes bio-analytical methods development. Prior to Pharmax Group, he was in the Pharmacology Department, University of Connecticut Health Center, where he synthesized and developed novel bio-conjugates for bio-diagnostics applications.
Jay has a Ph.D. from Department of Chemical Technology, University of Bombay. He is a member of American Chemical Society (ACS). He has published several papers in leading journals and is a co-inventor of several patents.
Dr. Barton has experience in drug discovery and development of both small molecule and biological drug candidates in virology, immunology, inflammation, and cardiovascular diseases in the pharmaceutical and biotech industry as well as academic research and teaching experience. Most recently, he was Vice-President of Drug Discovery at A&G Pharmaceuticals, a biologics and diagnostics company. He retired at the Director level after 20 years at Boehringer Ingelheim Pharmaceuticals. During his time at Boehringer Ingelheim he performed drug development pre-clinical studies on nevirapine (Viramune), a non-nucleoside inhibitor of HIV reverse transcriptase and an important HIV drug.
Prior to joining Boehringer Ingelheim, he was on the faculty at the University of Connecticut Medical School where he was the recipient of an NIH Career Development Award conducting research and teaching in immunology. Dr. Barton has authored over 80 scientific publications, and has been the principal investigator leading to 5 patents. He has a Ph.D. in biochemistry from the University of Tennessee at Oak Ridge National Laboratory and a B.A. from Indiana University.
Dr. Mak Jawadekar has been serving as a strategic advisor to pharmaceutical and biotechnology companies through his independent consultancy since 2010. He has over 35 years of experience in the Pharma Industry spanning both Business and Research activities. He has extensive experience in joint ventures, alliance management, contracting, outsourcing, benchmarking, performance metrics, pharmaceutical research and development, drug delivery technologies, formulations, clinical supply manufacturing and packaging, clinical trial materials, pharmaceutics, and pharmaceutical sciences. He also has deep knowledge and global experience working across the United States, Europe, India, and other parts of Asia, including Japan and China. He has helped create several Pharma R&D Partnerships, Joint Ventures, and Collaborations during his career.
Prior to his consultancy practice, Dr. Jawadekar was at Pfizer, Inc., as Director, Portfolio Management & Analytics, and as Vice President, Asia Colleague Resource Group, in the Pfizer Global R&D division. Mak held roles of increasing responsibility from 1982 to 2010 while at Pfizer, in technical, management, and business development positions. In these roles, he has worked in the areas of Drug Delivery Technology Assessment, Strategic External Alliance Management, Strategic CMC, Pharma R&D, Clinical Manufacturing, Manufacturing Technology Transfer and Scale-up, beginning as a research scientist in formulations development.
Dr. Jawadekar has presented at many professional meetings and has participated in various Panel Discussions/Round Tables around the globe. US President George W. Bush invited Dr. Jawadekar to accompany him on a trip to India in 2006. Recently, he accompanied Honorable Congressman Todd Rokita (R) Indiana, on a business mission to India in 2019. He has accompanied Presidents of Pfizer R & D to India in 2007 and also in 2009. During February 2018, he worked with Mr. Tonino Lamborghini, Chairman, Tonino Lamborghini S.p.A. of Italy to establish strategic collaborations in India, working through India's Prime Minister Narendra Modi.
Dr. Jawadekar holds a Ph.D. in Pharmaceutics from the University of Minnesota, and was honored with an honorary D.Sc. degree by DYP Mumbai University, recommended by the President of India, in February, 2011.
Mr. Todd Rokita is currently co-owner and General Counsel and Vice President of External Affairs, Apex Benefits Group, Inc. (2019- Present), where he serves as a member of the executive team and the corporate board.
Previously, Mr. Rokita was elected to the United States Congress as a Representative from the State of Indiana, for four consecutive terms since 2010, from the fourth congressional district. He was chosen by peers in the U.S. House of Representatives to serve on several House Committees.
Mr. Rokita has extensive executive, team-building, business strategy, and fiscal management expertise in the private sector, alongside his public service leadership experience. Mr. Rokita serves or has served as a Member of the Board of Directors of several commercial and charitable institutions.
Mr. Zucker is a Partner at CFO Financial Partners, LLC (https://www.cfopartners.com/), a firm that provides outsourced CFO (Chief Financial Officer), Controller and Financial Operations services as well as back office reporting and bookkeeping services for public and private companies, broker dealers, hedge funds, and family offices and high net worth individuals, among others. Mr. Zucker also serves as the CFO and Financial Operations Principal for numerous broker dealers and hedge funds. In addition to and simultaneously therewith, Mr. Zucker has served as a Partner at RRBB Accountants & Advisors, (aka Rosenberg Rich Baker Berman & Co.), a full-service accounting, advisory and consulting firm located in Central New Jersey. He has over thirty years of experience as a CPA specializing in the securities industry.. From 1983 through 1986, Mr. Zucker was a Senior Consultant at Deloitte Haskins and Sells and at Price Waterhouse from January 1987 through September 1989. He has previously served as the President and Chairman of Atlantis Business Development Corp. (ABDV), CFO of Natcore Solar Technology, Inc. (NTCXF) and as a Managing Director of American Frontier Financial Corp. (EVIS). Since May 2018, he has been serving as the CFO of EIG Energy Partners Capital Markets, LLC. Brian holds a CPA in States of New Jersey and New York, and holds several FINRA licenses. He is on the Board of Directors of National Investment Banking Association (NIBA). Mr. Zucker obtained a B.S. in Public Accounting from Pace university.
NanoViricides, Inc. (NYSE American: NNVC) is a clinical-stage biopharmaceutical innovator pioneering the next generation of broad-spectrum antiviral therapeutics. Its proprietary nanoviricide® technology introduces a novel “Bind–Encapsulate–Destroy” mechanism designed to neutralize viruses before they infect human cells.
The company’s lead candidate, NV-387, has demonstrated exceptional safety and efficacy in preclinical and clinical studies, targeting RSV, COVID-19, Influenza, and MPox/Smallpox. Alongside, NV-HHV-1 is advancing toward clinical readiness for Shingles and other Herpes-related infections.
With a cGMP-compliant in-house manufacturing facility in Shelton, CT, NanoViricides can rapidly scale production from clinical to market supply, allowing faster commercialization.
By addressing multiple high-impact viral diseases through a single technology platform, NanoViricides positions itself as a key player in global antiviral preparedness and innovation.
i - https://finance.yahoo.com/news/measles-drug-strong-activity-without-124500247.html
ii - https://finance.yahoo.com/news/nanoviricides-dual-track-clinical-strategy-124500503.html
iii - https://abcnews.go.com/Health/us-measles-cases-hit-highest-number-33-years/story?id=123564379
iv - https://www.paho.org/en/documents/situation-report-mpox-multi-country-outbreak-region-americas-31-january-2025
v - https://www.cognitivemarketresearch.com/covid-19-therapeutics-market-report
vi - https://finance.yahoo.com/news/respiratory-syncytial-virus-therapeutics-market-140000104.html
vii - https://www.databridgemarketresearch.com/reports/global-influenza-drug-market
viii - https://www.precedenceresearch.com/hiv-drugs-market
ix - https://www.databridgemarketresearch.com/reports/global-hepatitis-c-market
x - https://www.grandviewresearch.com/industry-analysis/herpes-simplex-virus-treatment-market-report
xi - https://www.futuremarketinsights.com/reports/eye-infections-treatment-market
xii - https://www.expertmarketresearch.com/reports/neglected-tropical-disease-treatment-market
xiii - https://www.industryarc.com/Report/17425/ebola-marburg-infections-market.html
xiv - https://finance.yahoo.com/news/strong-business-case-phase-ii-103000363.html
xv - https://www.nanoviricides.com/about-us
xvi - https://finance.yahoo.com/news/nanoviricides-inc-filed-annual-report-124500981.html
xvii - https://simplywall.st/stocks/us/pharmaceuticals-biotech/nysemkt-nnvc/nanoviricides/health
xviii - https://www.nanoviricides.com/Investor%20Info/pipeline
Equiscreen, LLC research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on publicly available data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Furthermore, some of the content on this website may contain forward-looking statements found in information made publicly available by the companies we highlight. This forward looking information fits within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding future possible events, expected continual growth of a company, the potential value of its securities, and look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company’s actual results of operation. We therefore strongly encourage that you visit and review any and all financial information made publicly available by highlighted companies.
Any opinions expressed in Equiscreen, LLC reports, company profiles, or other investor relations materials and presentations are subject to change, are expressed and given as of the date of publication, and we disclaim any obligation to advise you of any change in any information contained herein. Equiscreen, LLC and its affiliates may buy and sell shares of securities or options and warrants of the companies mentioned on this website at any time.
The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, Equiscreen, LLC, our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information).
Stock market investing is inherently risky. Equiscreen, LLC and its affiliates are not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print. We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov. and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca. and/or the British Columbia Securities Commission (“BCSC”) at https://www.bcsc.bc.ca/.
Equiscreen, LLC has been compensated by Interactive Offers, LLC to engage in investor awareness services for NanoViricides, Inc. (NYSE American: NNVC). NNVC is a client of Interactive Offers, LLC. A beneficial owner of Equiscreen, LLC is a minority stakeholder of Interactive Offers, LLC, owning less than 10%. Equiscreen, LLC and its affiliates are not affiliates or control persons of Interactive Offers, LLC. Equiscreen, LLC has been compensated $7,500 by Interactive Offers, LLC to engage in investor awareness services for NanoViricides, Inc. (NYSE American: NNVC). Equiscreen and its affiliated entities and partners have been compensated a total of $24,500 related to the engagement of investor awareness services for NNVC. Equiscreen, LLC and its partners and affiliates may buy and sell shares of securities or options and warrants of the companies mentioned on this website at any time.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. of Equiscreen, LLC investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services based on the publicly available information of our clients and prepared by our partners.